menu

Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Low-risk myelodysplastic syndrome (LR-MDS) is an acquired bone marrow disorder that manifests with symptomatic anemia. Many patients become dependent on red blood cell transfusions. Erythropoiesis-stimulating agents (ESAs) are the first-line treatment, but not all patients with LR-MDS respond to ESAs, and many become refractory to ESAs over time. Although advances have been made in the treatment of anemia in patients with MDS, there remains a significant unmet need for new and better treatment options for patients with ESA-refractory, transfusion-dependent MDS.

    Timely identification of patients who become ESA refractory is critical for primary care physicians to promptly request referral to hematology specialists. Delays in referral can contribute to increased disease burden and lower quality of life (QoL) for patients. To achieve optimal patient outcomes requires multi-disciplinary team-based management and collaboration among primary care and hematology specialty care providers. With recent FDA approvals and emerging positive trial data, the multi-disciplinary care teams are faced with learning how to integrate new treatment options and associated guidelines into real-world clinical practice thus making clinical decision-making much more complex.

    This educational activity, featuring an expert panel discussion, will review the identification of ESA failure in patients with LR-MDS and the importance of timely referral to hematology specialists.  Also presented will be emerging evidence from recent clinical trials surrounding the effectiveness and optimal use of novel therapies in ESA-refractory LR-MDS presented at major hematology/oncology medical meetings that could have implications on current and future interprofessional care team treatment planning.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an  activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Paul P. Doghramji, MD, FAAFP reported a financial interest/relationship or affiliation in the form of Consultant: Eisai, Inc. and Idorsia Pharmaceuticals, Ltd.  Speaker’s bureau member of: Eisai, Inc., Idorsia Pharmaceuticals, Ltd., Axiom Pharmaceuticals, Inc., Jazz Pharmaceuticals, and Abbvie. Stocks: Pfizer.

    Rami Komrokji, MD reported a financial interest/relationship or affiliation in the form of Advisor; AbbVie, Bristol-Myers Squibb Company, CTI BioPharma Corporation, Geron, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pharma Essentia, Servier, Taiho Pharmaceutical Co., Ltd., Rigel Pharmaceuticals. Speaker; AbbVie, CTI BioPharma Corporation, Jazz Pharmaceuticals, Pharma Essentia, Servier. Research grant; Bristol-Myers Squibb Company.

    Allan Platt, PA-C, MMSc, has no real or apparent conflicts of interest to report.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months: Linda  Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Melissa Duffy, PA-C hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This initiative is designed for primary care physicians, hematologists, hematology oncologists, pathologists, advanced practice providers (including nurses and physician assistants), pharmacists, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with LR-MDS and anemia complications.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify patients with LR-MDS and anemia that is refractory to ESA therapy using a team-based approach
    • Analyze real-world data surrounding the prompt use of novel and emerging therapies for transfusion-dependent, ESA-refractory LR-MDS, including proper dose escalation
    • Attain transfusion independence in patients with transfusion-dependent, ESA-refractory LR-MDS by integrating novel therapies into treatment plans based on updated clinical data
    • Interpret emerging evidence in ESA-naive LR-MDS
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits.  Approval is valid until July 6, 2024. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 0.25 contact hour of continuing pharmacy education JA4008106-0000-23-009-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Bristol-Myers Squibb Company

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • FDA Approval August 2023: Luspatercept as First-line Treatment

    For the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Low-risk myelodysplastic syndrome (LR-MDS) is an acquired bone marrow disorder that manifests with symptomatic anemia. Many patients become dependent on red blood cell transfusions. Erythropoiesis-stimulating agents (ESAs) are the first-line treatment, but not all patients with LR-MDS respond to ESAs, and many become refractory to ESAs over time. Although advances have been made in the treatment of anemia in patients with MDS, there remains a significant unmet need for new and better treatment options for patients with ESA-refractory, transfusion-dependent MDS.

    Timely identification of patients who become ESA refractory is critical for primary care physicians to promptly request referral to hematology specialists. Delays in referral can contribute to increased disease burden and lower quality of life (QoL) for patients. To achieve optimal patient outcomes requires multi-disciplinary team-based management and collaboration among primary care and hematology specialty care providers. With recent FDA approvals and emerging positive trial data, the multi-disciplinary care teams are faced with learning how to integrate new treatment options and associated guidelines into real-world clinical practice thus making clinical decision-making much more complex.

    This educational activity, featuring an expert panel discussion, will review the identification of ESA failure in patients with LR-MDS and the importance of timely referral to hematology specialists.  Also presented will be emerging evidence from recent clinical trials surrounding the effectiveness and optimal use of novel therapies in ESA-refractory LR-MDS presented at major hematology/oncology medical meetings that could have implications on current and future interprofessional care team treatment planning.

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an  activity. 

    AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

    Paul P. Doghramji, MD, FAAFP reported a financial interest/relationship or affiliation in the form of Consultant: Eisai, Inc. and Idorsia Pharmaceuticals, Ltd.  Speaker’s bureau member of: Eisai, Inc., Idorsia Pharmaceuticals, Ltd., Axiom Pharmaceuticals, Inc., Jazz Pharmaceuticals, and Abbvie. Stocks: Pfizer.

    Rami Komrokji, MD reported a financial interest/relationship or affiliation in the form of Advisor; AbbVie, Bristol-Myers Squibb Company, CTI BioPharma Corporation, Geron, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Pharma Essentia, Servier, Taiho Pharmaceutical Co., Ltd., Rigel Pharmaceuticals. Speaker; AbbVie, CTI BioPharma Corporation, Jazz Pharmaceuticals, Pharma Essentia, Servier. Research grant; Bristol-Myers Squibb Company.

    Allan Platt, PA-C, MMSc, has no real or apparent conflicts of interest to report.

    The directors, planners, managers, and reviewers reported the  following financial relationships they have with any ineligible  company of any amount during the past 24 months: Linda  Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Melissa Duffy, PA-C hereby state that they do not have any financial relationships or relationships with any ineligible company of any amount during the past 24 months.  Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.

  • Target Audience

    This initiative is designed for primary care physicians, hematologists, hematology oncologists, pathologists, advanced practice providers (including nurses and physician assistants), pharmacists, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with LR-MDS and anemia complications.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Identify patients with LR-MDS and anemia that is refractory to ESA therapy using a team-based approach
    • Analyze real-world data surrounding the prompt use of novel and emerging therapies for transfusion-dependent, ESA-refractory LR-MDS, including proper dose escalation
    • Attain transfusion independence in patients with transfusion-dependent, ESA-refractory LR-MDS by integrating novel therapies into treatment plans based on updated clinical data
    • Interpret emerging evidence in ESA-naive LR-MDS
  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

     

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits.  Approval is valid until July 6, 2024. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 0.25 contact hour of continuing pharmacy education JA4008106-0000-23-009-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    Provided by AXIS Medical Education.

  • Commercial Support

    This activity is supported by an educational grant from Bristol-Myers Squibb Company

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

  • FDA Approval August 2023: Luspatercept as First-line Treatment

    For the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule20 Jun 2024